On Friday, Gilead Sciences, Inc. GILD revealed data from a two-and-a-half-year interim analysis from the ongoing Phase 3 ASSURE study evaluating the long-term efficacy and safety of Livdelzi.The study showed that 81% (30 out of 37) of participants with primary biliary cholangitis (PBC) treated with Livdelzi (seladelpar) achieved a composite biochemical response (CBR), demonstrating significant improvements in a key measures of PBC progression.Additionally, 41% (15 out of 37) of participants achieved normali ...